Quidel - QDEL STOCK NEWS

QuidelOrtho Corporation (Nasdaq: QDEL) announced preliminary revenue results for the first quarter of 2023, with total revenues expected to be between $840 million and $850 million. Respiratory product revenue is projected at $262 million to $267 million, which includes $212 million to $217 million from COVID-19 products. Non-respiratory product revenue is forecasted to be $578 million to $583 million, reflecting a 5% increase on a combined basis. This growth was primarily driven by the Labs business unit, aided by a $21 million settlement related to a collaboration agreement. The Company will report full financial results and conduct a conference call on May 3, 2023.

QuidelOrtho Corporation (Nasdaq: QDEL) has announced the formation of the QuidelOrtho Women’s Leadership Network (QWLN), celebrating Women’s History Month. This global network includes 14 leaders and 16 chapters worldwide, focusing on mentoring and empowerment for women. The initiative stems from the merger of Quidel Corporation and Ortho Clinical Diagnostics in 2022, aiming to enhance professional development. CEO Douglas Bryant emphasized the network's role in fostering personal and professional growth. The QWLN offers various programs, including training and community events, to unite women across regions.

QuidelOrtho Corporation (Nasdaq: QDEL) has received FDA De Novo clearance for its Sofia 2 SARS Antigen+ FIA, marking it as the first rapid antigen test for COVID-19 to achieve this status. The test, designed for symptomatic individuals, uses anterior nasal swabs and provides results in just 10 minutes. It can be performed in clinical labs and point-of-care settings by trained personnel. The Sofia 2 analyzer enhances testing efficiency with two operational modes and connects to Virena for real-time data management. This development reinforces QuidelOrtho's position in the diagnostic market as they continue to innovate in COVID-19 testing.

QuidelOrtho Corporation (Nasdaq: QDEL) has announced its participation in the Raymond James & Associates’ 44th Annual Institutional Investors Conference in Orlando, Florida on March 7, 2023. Douglas Bryant, the company’s president and CEO, will engage in a fireside chat at 11:35 a.m. ET / 8:35 a.m. PT. Investors can access a live webcast and replay on the company’s Investor Relations page. QuidelOrtho is a leader in in vitro diagnostics, committed to enhancing patient outcomes globally.

On February 27, 2023, ImageMover announced a partnership with QuidelOrtho to enhance pharmacist-administered testing for various illnesses, including COVID-19 and influenza. This collaboration integrates QuidelOrtho's Sofia 2 analyzer with ImageMover's Workflow Services, enabling pharmacies to onboard patients 80% faster and streamline testing processes. The Sofia 2 offers testing results in 3-15 minutes and supports a wide test menu suitable for pharmacies and healthcare settings. Both companies aim to expand healthcare access, particularly in underserved areas, addressing challenges faced by pharmacists in offering test-to-treat programs.

QuidelOrtho Corporation (Nasdaq: QDEL) reported a 36% increase in fourth quarter revenue of $866.5 million, up from $636.9 million in Q4 2021. For the full year, revenue reached $3.27 billion, a 92% increase driven by Point of Care and Molecular Diagnostics, despite a decline in Labs due to China lockdowns. The fourth quarter GAAP EPS decreased to $0.45, down from $6.85 YoY, while adjusted EPS fell to $1.76, a 66% decline. The company anticipates strong integration progress and growth opportunities in 2023, providing 2023 financial guidance.

QuidelOrtho Corporation (Nasdaq: QDEL) announced preliminary unaudited revenue results for Q4 and FY 2022. Q4 revenues are projected between $853 million and $868 million, with COVID-19 product revenues expected between $124 million and $134 million. For FY 2022, total revenues are anticipated to be between $4,038 million and $4,053 million, marking a significant 502% increase on a GAAP basis. The company emphasizes strong growth in Molecular Diagnostics and Point of Care segments.

QuidelOrtho Corporation (Nasdaq: QDEL) will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 9, 2023, at 9:00 a.m. PST / 12:00 p.m. EST. The presentation will be accessible via a live webcast on QuidelOrtho’s Investor Relations page. QuidelOrtho, a leader in in vitro diagnostics, focuses on innovative technologies for healthcare diagnostics, enhancing patient outcomes globally.

QuidelOrtho Corporation (Nasdaq: QDEL) announced that Health Canada has approved the Quidel TriageTrue High-Sensitivity Troponin I (hsTnl) Test on the Quidel Triage MeterPro platform. This assay, able to provide results in under 20 minutes, enhances the diagnosis of myocardial infarction with high sensitivity and precision. As the first of its kind on a compact analyzer in Canada, it promises faster patient care and improved emergency department efficiency. QuidelOrtho aims to elevate diagnostic testing and patient outcomes.